Taiwan’s Bora Pharmaceuticals (TWSE: 6472) is to acquire Upsher-Smith Laboratories, a US generics manufacturer.
Bora is to buy the firm from shareholders Sawai Group Holdings (TYO: 4887) and Sumitomo Corporation (TYO: 8053) for up to $210 million.
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth and Maple Grove, Minnesota. The company has solid manufacturing capabilities, a robust distribution network, and established commercial relationships.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze